On Thursday, the U.S. Food and Drug Administration (FDA) approved the drug Cobenfy which targets schizophrenia in a new way.
The FDA approved Cobenfy, a new drug for people with schizophrenia that comes with fewer side effects than other ...
Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...
The U.S. Food and Drug Administration (FDA) on Thursday approved the first new drug to treat people with schizophrenia in ...
Bristol Myers Squibb's drug, KarXT, improved symptoms of adults with schizophrenia and had fewer side effects than ...
The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the ...
The U.S. Food and Drug Administration (FDA) on Friday approved a new drug used for treating schizophrenia in adults, ...
On Thursday, the U.S. Food and Drug Administration approved COBENFY, an oral medication that marks the first new class of ...
Despite billions of taxpayer dollars spent on mental illness research, Cobenfy was developed by a private biopharmaceutical ...
Cobenfy is the first schizophrenia drug in decades to treat the mental health condition in a new way, with potentially fewer ...
Experts expressed enthusiasm Friday after US health regulators approved the first new form of treatment for schizophrenia in ...
The US Food and Drug Administration has approved Cobenfy, also known as KarXT, a new schizophrenia treatment. The drug was ...